Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391874 | 0.82 | AGXT (0.42) | AGXTLMNADPP4ALDH1A1PDE10A | |
| SCHEMBL3799664 | 0.78 | AGXT (0.44) | AGXTDPP4ALDH1A1 | |
| SCHEMBL7952261 | 0.78 | AGXT (0.62) | AGXTALDH1A1PDE10AKDM4ESMN1; SMN2 | |
| SCHEMBL3392251 | 0.77 | AGXT (0.41) | AGXTLMNAKDM4E | |
| SCHEMBL9688618 | 0.77 | AGXT (0.45) | AGXTDPP4ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL2111401 | 0.77 | AGXT (0.45) | AGXTDPP4ALDH1A1KDM4E | |
| SCHEMBL2112911 | 0.74 | AGXT (0.45) | AGXTDPP4ALDH1A1PDE10A | |
| SCHEMBL3796812 | 0.73 | AGXT (0.42) | AGXTDPP4ALDH1A1KDM4E | |
| SCHEMBL3393909 | 0.73 | LMNA (0.44) | AGXTLMNAALDH1A1PDE10AKDM4E | |
| SCHEMBL18174873 | 0.71 | CA2 (0.44) | LMNAALDH1A1PRKCEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| US-7138401-B2 | 2-aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | HSP90AB2P, HSP90AB1, HSP90AA1 | AGXT 1906/4885LMNA 4492/4885DPP4 3812/4885 |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | HSP90AB2P, HSP90AB1, HSP90AA1 | AGXT 1906/4885LMNA 4492/4885DPP4 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.